HNRNPA2B1 controls an unfolded protein response-related prognostic gene signature in prostate cancer

Foster JG, Gea EEM, Labiba MA, Anene CA, Stockley J, Philippe C, Cereda M, Rouault-Pierre K, Leung HY, Bessant C, Rajan P BioRXiv pre-print 2022 

FOXA1 regulates alternative splicing in prostate cancer

Foster JG*, Del Giudice M*, Peirone S, Rissone A, Caizzi L, Gaudino F, Parlato C, Anselmi F, Arkell R, Guarrera S, Oliviero S, Basso G, Rajan P*, Cereda M* Cell Reports 2022 Sep 27;40(13):111404.

A HIF-LIMD1 negative feedback mechanism mitigates the pro-tumorigenic effects of hypoxia

Foxler DE, Bridge KS, Foster JG, Grevitt P, Curry S, Shah KM, Davidson KM, Nagano A, Gadaleta E, Rhys HI, Kennedy PT, Hermida MA, Chang TY, Shaw PE, Reynolds LE, McKay TR, Wang HW, Ribeiro PS, Plevin MJ, Lagos D, Lemoine NR, Rajan P, Graham TA, Chelala C, Hodivala-Dilke KM, Spendlove I, Sharp TV. EMBO Molelcular Medicine 2018 Aug;10(8).

Argonaute Utilization for miRNA Silencing Is Determined by Phosphorylation-Dependent Recruitment of LIM-Domain-Containing Proteins

Bridge KS, Shah KM, Li Y, Foxler DE, Wong SCK, Miller DC, Davidson KM, Foster JG, Rose R, Hodgkinson MR, Ribeiro PS, Aboobaker AA, Yashiro K, Wang X, Graves PR, Plevin MJ, Lagos D, Sharp TV. Cell Reports 2017 Jul 5;20(1):173-187.

Mitochondrial Superoxide Generation Enhances P2X7R-Mediated Loss of Cell Surface CD62L on Naive Human CD4+ T Lymphocytes

Foster JG, Carter E, Kilty I, Mackenzie AB, Ward SG. Journal of Immunology 2013 Feb 15;190(4):1551-9.

Inhibition of PI3K signaling spurs new therapeutic opportunities in inflammatory/autoimmune diseases and hematological malignancies

Foster JG, Blunt MD, Carter E, Ward SG. Pharmacol Rev. 2012 Oct;64(4):1027-54